{"name":"ONY","slug":"ony","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1998-01-01","label":"Infasurf first approved","drug":"Infasurf","drugSlug":"calfactant","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aerosolized Calfactant","genericName":"Aerosolized Calfactant","slug":"aerosolized-calfactant","indication":"Acute respiratory distress syndrome (ARDS)","status":"phase_3"},{"name":"Infasurf","genericName":"CALFACTANT","slug":"calfactant","indication":"Respiratory distress syndrome in the newborn","status":"marketed"}]}],"pipeline":[{"name":"Aerosolized Calfactant","genericName":"Aerosolized Calfactant","slug":"aerosolized-calfactant","phase":"phase_3","mechanism":"Aerosolized calfactant is a pulmonary surfactant replacement therapy delivered directly to the lungs via inhalation to restore surfactant function and improve gas exchange.","indications":["Acute respiratory distress syndrome (ARDS)","Respiratory distress in premature infants (potential)"],"catalyst":""},{"name":"Infasurf","genericName":"CALFACTANT","slug":"calfactant","phase":"marketed","mechanism":"","indications":["Respiratory distress syndrome in the newborn"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSHN2dGgwQnktenJHakRZUFBnSXpkYjJ0c19SOURTWWtFZ1NUWVR0Q0NpZXlQMVRKU2N2ay1ETmRUU2VCLUVfZUZSUW9kTjl6S0pERU9VWE4tMC1tLVpqOV91NGhETXd5VnNDOGJnWnRiSF9VdmhTY3BhNUpnYjFERjlGc19OMUlZemdwQUFEYXZMR0hXZHFQVzNqWkpDLUJ3aE5rbzlxMUVpblVnSkNkSDNxbS1Cb0FoWXMwbGM2MHJ3MkY3dnpRekhCQndvRkk2clVlQUgtbw?oc=5","date":"2026-03-25","type":"pipeline","source":"MSN","summary":"UBS picks only one favourite in pharma sector; cuts target price for Cipla, Lupin and more - MSN","headline":"UBS picks only one favourite in pharma sector; cuts target price for Cipla, Lupin and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE4wMUFlOW15SWo0a05Qemx2TFZNQk9KbHV1M1lVR0l1U2h2QlVybUVDQWhNMFdJV1RiZ1F3TkItaDIwZEdhdWdQelJXbVFldmNWb2dDWkpkZldLbFJnSzdhWWVoa0JjTnpHWkNNaWw4RWJiSlRDalE?oc=5","date":"2026-01-23","type":"trial","source":"Endpoints News","summary":"Lilly was the only pharma bidder for Ventyx - Endpoints News","headline":"Lilly was the only pharma bidder for Ventyx","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-14","type":"pipeline","source":"ET Pharma","summary":"India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence - ET Pharma","headline":"India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-09","type":"pipeline","source":"The New Indian Express","summary":"Cough syrup deaths linked to lapses at Sresan Pharma; TN begins inspection of 300 drug units - The New Indian Express","headline":"Cough syrup deaths linked to lapses at Sresan Pharma; TN begins inspection of 300 drug units","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUWgybXNXRktwaFc0VUdsMVhRSjVLbjgwOHpGNl9aNDZpb0RIRTZneGlyVXFSaVlkS1hOQ2tueFRZelZqN29XeGtFU0NlYy1aaFVzZkRMQ0xLMHZHWlJ0bEF5dGVyRkNmU1JoekRiXzJpZ2pHS2VpQUZJMnFhdVdKRUJCbWdZUXN3UTBGNGs5RFY3QXlFb2k2ZDY4cHRRTmpxMlNJRlV3b0pJOEpWVEFSYTl4QzRQUlQzWmZj?oc=5","date":"2025-10-06","type":"pipeline","source":"Fierce Pharma","summary":"Amgen unveils DTC platform with 60% discount on Repatha, giving US lowest price of G7 nations - Fierce Pharma","headline":"Amgen unveils DTC platform with 60% discount on Repatha, giving US lowest price of G7 nations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNRmNBc1BRWDZlSG0yYWRRTndnUzIzclkzQXF5dlUzLWNVZllVLUdUaGdMYVhta0NtTHhib19mS0hQUVd1SVd1bzN0VlZEb0I5V1pjOG1tWERWbV9pN3RTbHVSZ05OT2VQaDBLSldaX1g4WXE0LUlaRTU0ci1Hb0RkYTNTQjlHLTFYcUsxYmtKUklrZ1lhSzR0OFNHak5idXBGZWo0Z19aaDZoTHh4ZW90NQ?oc=5","date":"2025-10-06","type":"trial","source":"Endpoints News","summary":"Metsera got less than it wanted from Pfizer in long-awaited obesity biotech acquisition - Endpoints News","headline":"Metsera got less than it wanted from Pfizer in long-awaited obesity biotech acquisition","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQanhaTEN3M2I1cElyMkNGdVFoUmFMZERBbV9ndWdxTkFKWFNqVWpwWGJUdmtTZFJOd2tsWkZsbk9IQkFTbkN6dENTRk1nUlUyU292U2g0ZThsemZrYld2amdpaXlMR2E0TzJ3dmRVSldvZGlhSGExR0ZRdHg0bWdBUE8xX1pjYnVnRDltc3dlcGZPUQ?oc=5","date":"2025-02-10","type":"pipeline","source":"Yale Insights","summary":"What Investors Are Missing about Pfizer and Merck - Yale Insights","headline":"What Investors Are Missing about Pfizer and Merck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcTdCWnpDY0RxelJoeHdvV0NrRWJlU3ZHSjdyMmV4MkpqeVFKa3E2X1ZCekV5Q1lIR1lMdTRSeHpuYnNVNEVIQlBUQk1WYXBKTkd5V1FhZFJPS1VIaDA0STlZTHVpclo4TVVndm55cGVsR2NsX0hrLVJpaU5VRnlxS2JjbzlrYlJDMkhraktWVVdvWmpSMWFHcDRBcGsyZzBJQ1dyNnRXVC1TLWM?oc=5","date":"2025-02-10","type":"pipeline","source":"ADWEEK","summary":"Pharma Makes its Mark on the Super Bowl—But Not Without Controversy - ADWEEK","headline":"Pharma Makes its Mark on the Super Bowl—But Not Without Controversy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5HMExBNWFfR0Ryd1lMVzItNUVaOTJfUjhfYm9xQkgzTWdiaEhJUXRManYtZ2Zha2lKMmFrbWtwZFlfMjA0elZoN1VQSGlQTWJWN2JBX0dGRVV4d3JBUXQxUDRsTWNpSDZhQ0lrbk9HamxTQXZkQVRNVW1NNjU3VFE?oc=5","date":"2024-06-03","type":"pipeline","source":"Fierce Pharma","summary":"The top 10 pharma drug ad spenders for 2023 - Fierce Pharma","headline":"The top 10 pharma drug ad spenders for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQ2hKaWVwaGNFU1BLTm85WERqenNaaXRSTFRkeGFZMWhFY0tWaVRZdmVLQTMwWVMwU05UVlFXU1prbUlwdm9uSkxqeHdPWm9QTUt1aHktRERKdGZHcjhNMUVhM1doenpJbWJ5NXVOX2ZFSUczT3dJYUgyU0VxT21seWJBbzNlQzh6dm5aaC1HcXZpaDd4Y2dxN01OVmhVRFNfeVpz?oc=5","date":"2024-05-29","type":"pipeline","source":"psychiatrictimes.com","summary":"Onyda XR: The First and Only Liquid Nonstimulant ADHD Medication - psychiatrictimes.com","headline":"Onyda XR: The First and Only Liquid Nonstimulant ADHD Medication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNM1lzeHlDbm50OWlfOHE2b3dWcU9Pd1hXMWZETElQV191bnpQdkJrb3BVaWdYRXdUX0l0V2htWHo2ODNZYS10OFowc0FYU0F6T3VOLWJrYmowTDV2WUZsQllOREJiZUt3N1BDYnNUN1FRcjBZb2dNLUlpTmUtaXhEZU5QWU8yMGFKV2pVWjhLQ1FfOS1TVVMyME5EN2hSYmVVTXc?oc=5","date":"2020-08-19","type":"trial","source":"Applied Clinical Trials","summary":"How Social Media is Transforming Pharma and Healthcare - Applied Clinical Trials","headline":"How Social Media is Transforming Pharma and Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9iOHpyX0hvRGZuTnV4MHBFTEhWWlFZd1FSR1VwYkNCMS14aFltMjAxWkNjU0pDaE94NGQ4SC1GcW1aUHFWdkgxT3FrU1VWNFFIVVpJX3lXeE5XM0NMcmkwb3owcTNGY01kSWc0Z01uUTVYeWpUcWI2ZQ?oc=5","date":"2014-03-27","type":"pipeline","source":"Science | AAAS","summary":"A Look Back at Big Pharma Stocks - Science | AAAS","headline":"A Look Back at Big Pharma Stocks - Science | AAAS","sentiment":"neutral"},{"date":"2005-01-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2004-11-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}